Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer
Abstract
Itraconazole has been repurposed as an anticancer therapeutic agent for multiple malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits Hedgehog pathway activity. We performed a window-of-opportunity trial to determine the biologic effects of itraconazole in human patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1916
Entities
People
- Brandon Faubert
- Chul Ahn
- Chyndhri Padmanabhan
- David E. Gerber
- Farjana J. Fattah
- Indhumathy Subramaniyan
- Ivan Pedrosa
- James Kim
- Jessica M. Saltarski
- Kemp H. Kernstine
- Lorraine Pelosof
- Qing Yuan
- Quyen N. Do
- Rachael Skelton
- Raja Reddy Kallem
- Ralph J DeBerardinis
- Richard D. Leff
- Robert E. Lenkinski
- Rolf Brekken
- Sahba Kasiri
- Scott I Reznik
- Vaidehi Chembukar
- William C Putnam
- Yin Xi
Organizations
- American Cancer Society
- Canadian Institutes of Health Research
- Cancer Prevention and Research Institute of Texas
- Comprehensive Cancer Center, City of Hope
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Texas Tech University Health Sciences Center
- United States Department of Defense
- University of Texas Southwestern Medical Center
- University of Texas at Austin